Cardivia Labs Inc

Cardivia Labs is a biotechnology company based in Rochester, New York, focused on developing next-generation RNA therapeutics to reverse vascular aging and treat cardiovascular diseases.

We are pioneering a revolutionary approach to cardiovascular health, targeting the genetic drivers of vascular decline with precision RNA medicines. Our core technology, including Target-Site Blockers (TSBs) and Antisense Oligonucleotides (ASOs), aims to restore vascular health and extend cardiovascular healthspan.

Cardivia Labs’ proprietary miRNA-targeting strategy and cell-specific vascular targeting offer a unique advantage in developing therapies for conditions like atherosclerosis and vascular aging. Our team, led by scientist-founder Ismail Cimen, is dedicated to translating cell-targeted RNA therapeutics into impactful treatments.

Currently, we are advancing programs targeting CXCR4, SIRT6, and TET2, with an IND-enabling study planned for CXCR4-TSB. We are committed to transforming outcomes for millions at risk of heart attack and stroke.